Email this article The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection
- Authors: Lioznov D.A.1,2, Tokin I.I.1,3, Zubkova T.G.1, Sorokin P.V.4
-
Affiliations:
- Smorodintsev Research Institute of Influenza
- Pavlov First Saint Petersburg State Medical University
- Mechnikov North-Western State Medical University
- LLC «Azol Pharma»
- Issue: Vol 92, No 12 (2020)
- Pages: 160-164
- Section: Articles
- URL: https://journals.rcsi.science/0040-3660/article/view/60288
- DOI: https://doi.org/10.26442/00403660.2020.12.200427
- ID: 60288
Cite item
Full Text
Abstract
Aim. Evaluation of efficacy, safety, tolerability, and determination of the optimal dose of riamilovir in patients diagnosed with acute respiratory viral infection (ARVI).
Materials and methods. The study included 270 patients with uncomplicated ARVI of mild and moderate severity (with a laboratory-confirmed PCR method for the presence of ARVI antigens, absence of influenza virus antigens). Patients were included in the study after signing an informed consent. Patients were randomized into 3 groups in a 1:1:1 ratio of 90 patients in each group. Completed the study in accordance with the Protocol: 267 patients. The study involved patients diagnosed with ARVI.
Results. Confirmed the efficacy, safety and tolerability of the drug riamilovir. Adverse drug reactions associated, in the opinion of the doctor, with taking the drug and resulting in discontinuation of the drug, were not noted in this study.
Conclusion. As a result of clinical study, the effectiveness of both ARVI treatment regimens with drug riamilovir has been shown. There were no differences in the effectiveness and safety of the proposed treatment regimens. Practical use of both treatment regimens is recommended. However, according to the authors, taking the drug 3 times a day is much more convenient for patients, improves the quality of life and adherence to therapy.
Full Text
##article.viewOnOriginalSite##About the authors
D. A. Lioznov
Smorodintsev Research Institute of Influenza; Pavlov First Saint Petersburg State Medical University
Email: pavel.sorokin@azolpharma.com
ORCID iD: 0000-0003-3643-7354
д.м.н., и.о. дир., зав. каф.
Russian Federation, Saint PetersburgI. I. Tokin
Smorodintsev Research Institute of Influenza; Mechnikov North-Western State Medical University
Email: pavel.sorokin@azolpharma.com
ORCID iD: 0000-0002-9824-3945
к.м.н., зав. отд-нием, доц. каф.
Russian Federation, Saint PetersburgT. G. Zubkova
Smorodintsev Research Institute of Influenza
Email: pavel.sorokin@azolpharma.com
ORCID iD: 0000-0001-8241-2567
к.м.н., зав. отд-нием
Russian Federation, Saint PetersburgP. V. Sorokin
LLC «Azol Pharma»
Author for correspondence.
Email: pavel.sorokin@azolpharma.com
ORCID iD: 0000-0002-1477-8521
к.фарм.н., ген. дир
Russian Federation, NovouralskReferences
- Калюжин О.В. Острые респираторные вирусные инфекции: современные вызовы, противовирусный ответ, иммунопрофилактика и иммунотерапия. М.: МИА, 2014 [Kalyuzhin OV. Acute respiratory viral infections: modern challenges, antiviral response, immunoprophylaxis and immunotherapy. Moscow: MIA, 2014 (In Russ.)].
- Роспотребнадзор о завершении эпидемического сезона по гриппу и ОРВИ 2015–2016 [Rospotrebnadzor (Federal Service for Supervision of Consumers Protection) on the end of the epidemic season for influenza and SARS (In Russ.)]. https://rospotrebnadzor.ru/about/info/news/news_details.php?ELEMENT_ID=5995&sphrase_id=638303
- ОРВИ и грипп у детей. Диагностика, профилактика, лечение. Пособие для врачей. М., 2014; с. 9 [Acute respiratory viral infections and influenza in children. Diagnostics, prevention, treatment. A guide for doctors Moscow, 2014; p. 9 (In Russ.)].
- Лыткина И.Н. Анализ заболеваемости гриппом и другими респираторными инфекциями по Москве в эпидсезон 2009–2010 гг. Еженедельный информационный бюллетень Роспотребнадзора. 2010;10:22-6 [Lytkina IN. Analysis of the incidence of influenza and other respiratory infections in Moscow in the 2009–2010 epidemic season. Weekly newsletter of Rospotrebnadzor. 2010;10:22-6 (In Russ.)].
- Деева Э.Г., Коновалова Н.И., Киселев О.И. Изучение противовирусной активности препарата Триазавирин в отношении респираторных вирусов. Триазавирин – противовирусный препарат нового поколения. Под ред. О.Н. Чупахина, О.И. Киселева. Екатеринбург, 2016; с. 69-73 [Deeva EG, Konovalova NI, Kiselev OI. Study of the antiviral activity of the drug Triazavirin against respiratory viruses. Triazavirin is a new generation antiviral drug. Edited by ON Chupakhin, OI. Kiselev. Yekaterinburg, 2016; p. 69-73 (In Russ.)].
- Дриневский В.П. Острые респираторные инфекции у детей и подростков: практическое руководств. СПб.: СпецЛит, 2013 [Drinevsky VP. Acute respiratory infections in children and adolescents: practical guidelines. Saint Petersburg: SpetsLit, 2013 (In Russ.)].
- Ершов Ф. Рациональная фармакотерапия гриппа и ОРВИ. Фармацевтический вестн. 2013;39:39-43 [Yershov F. Rational pharmacotherapy of influenza and acute respiratory viral infections. Pharmaceutical Bulletin. 2013;39:39-43 (In Russ.)].
- Киселев О.И., Деева Э.Г., Мельникова Т.И. и др. Новый противовирусный препарат Триазавирин. Результаты II фазы клинического исследования. Вопр. вирусологии. 2012;6:9-12 [Kise- lev O I, Deeva E G, Melnikova T I, et al. New antiviral drug Triazavirin. Results of the phase II clinical trial. Vopr. Virology. 2012;6: 9-12 (In Russ.)].
- Жаркова Н.Е. Симптоматическое лечение ОРВИ: будущее за комбинированными препаратами. Рус. мед. журн. 2007;22:16-9 [Zharkova NE. Symptomatic treatment of ARVI: the future of combined drugs. Rus. med. zhurn. 2007;22:16-9 (In Russ.)].
- Деева Э.Г., Киселев О.И., Мельникова Т.И. и др. Новый противовирусный препарат «Триазавирин». Результаты I фазы клинического исследования. Эпидемиология и инфекционные болезни. 2013;5:20-6 [Deeva EG, Kiselev OI, Melnikova T I, et al. New antiviral drug «Triazavirin». Results of the phase I clinical trial. Epidemiology and infectious diseases. 2013;5:20-6 (In Russ.)].
- Токин И.И., Зубкова Т.Г., Дроздова Ю.В., Лиознов Д.А. Опыт этиотропной терапии ОРВИ отечественным противовирусным препаратом. Инфекционные болезни. 2019;17(4):13-7 [Tokin II, Zubkova TG, Drozdova YuV, Lioznov DA. Experience of etiotropic therapy of ARVI with a domestic antiviral drug. Infectious disease (In Russ.)]. doi: 10.20953/1729-9225-2019-4-13-17
Supplementary files
